<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588688</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00160641</org_study_id>
    <nct_id>NCT04588688</nct_id>
  </id_info>
  <brief_title>Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency</brief_title>
  <official_title>Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobias Else</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers propose the use of mifepristone as an alternative way to test for Central&#xD;
      Adrenal Insufficiency (CAI). They want to assess the feasibility of recruitment and the&#xD;
      efficacy of the purposed method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of study participants recruited</measure>
    <time_frame>Study completion, approximately 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of study participants with complete study data captured</measure>
    <time_frame>Study completion, approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak cortisol measured</measure>
    <time_frame>Day 2</time_frame>
    <description>Serum cortisol will be collected the day after mifepristone administration and insulin tolerance test insulin tolerance test (ITT) if available</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Central Adrenal Insufficiency</condition>
  <condition>Mifepristone</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>KORLYMÂ®, C1073, RU486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (1 of the following):&#xD;
&#xD;
          -  Completed insulin tolerance testing (ITT) at University of Michigan from 2012 to&#xD;
             present.&#xD;
&#xD;
          -  Are scheduled to complete ITT.&#xD;
&#xD;
          -  Are clinically suspected to have adrenal insufficiency but have not undergone ITT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are of child-bearing potential (defined as a sexually mature woman&#xD;
             who has not undergone hysterectomy, bilateral oophorectomy bilateral salpingectomy or&#xD;
             bilateral tubal ligation/occlusion, at least 12 weeks prior to screening, or who has&#xD;
             not been naturally postmenopausal for at least 24 consecutive months prior to study&#xD;
             enrollment) and not using non-hormonal contraception.&#xD;
&#xD;
          -  Female patients not willing to use non-hormonal contraception for one month following&#xD;
             treatment.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding.&#xD;
&#xD;
          -  Patients with an existing diagnosis of adrenal insufficiency who are on any&#xD;
             glucocorticoid replacement other than oral hydrocortisone or prednisone.&#xD;
&#xD;
          -  Patients on medications that are strong CYP3A&#xD;
&#xD;
          -  Patients taking other medications metabolized by CYP3A&#xD;
&#xD;
          -  Patients who have a history of QT prolongation and patients with any recent abnormal&#xD;
             electrocardiogram (ECG).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Else, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Brand</last_name>
    <phone>734-647-1772</phone>
    <email>sabrand@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brand</last_name>
      <phone>734-647-1772</phone>
      <email>abrand@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Tobias Else, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Tobias Else</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Insulin Tolerance Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

